A pioneer in the development of mRNA technology, CureVac has spent more than two decades in exploring its potential in both prophylactic and therapeutic vaccine settings. David McCall, Senior Editor, Nucleic Acid Insights, discusses the promise of next-generation approaches with Chief Development Officer, Myriam Mendila.
No takes yet. Share an insight, caveat, or question.
Myriam Mendila (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: